|
||||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ENSG00000142627 |
Summary for EPHA2 |
Gene summary |
| Gene information | Ensembl ID | ENSG00000142627 | Gene symbol | EPHA2 |
| Gene name | EPH receptor A2 | |
| HGNC | 3386 | |
| Entrez ID | 1969 | |
| Gene type | protein_coding | |
| Synonyms | EPHA2| | |
| UniProtAcc | P29317 |
Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000142627 | EPHA2 | DB01254 | Dasatinib | SmallMoleculeDrug |
| ENSG00000142627 | EPHA2 | DB04395 | Phosphoaminophosphonic Acid-Adenylate Ester | SmallMoleculeDrug |
| ENSG00000142627 | EPHA2 | DB08896 | Regorafenib | SmallMoleculeDrug |
| ENSG00000142627 | EPHA2 | DB12010 | Fostamatinib | SmallMoleculeDrug |
Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
| ENSG00000142627 | EPHA2 | DB01254 | Dasatinib | SmallMoleculeDrug | Acute Lymphoblastic Leukemia (ALL),Chronic Myelogenous Leukemia (CML),Myeloproliferative Neoplasms |
| ENSG00000142627 | EPHA2 | DB08896 | Regorafenib | SmallMoleculeDrug | Colon Cancer,Rectal Cancer,Gastrointestinal Stromal Tumors,Liver Cancer |
Top |
Structure and expression level for EPHA2 |
AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure.∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
Landscape of gene expressions across multiple cancer types. |
Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| EPHA2 | 4.44e+03 | 1.35e+00 | 1.94e-01 | 6.96e+00 | 3.43e-12 | 5.88e-11 | THCA |
Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| EPHA2 | 1.11e+03 | -1.11e+00 | 9.31e-02 | -1.19e+01 | 8.45e-33 | 4.79e-32 | BRCA |
Top |
Sex-biased somatic mutation for EPHA2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for EPHA2 |
Landscape of DNA methylation across multiple cancer types. |
Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| MESO | cg26793227 | chr1:16157163 | CGI:chr1:16154989-16155965 | promoter | 6.07e-01 | 7.17e-01 | -1.99e+00 | 4.70e-02 | 4.92e-02 | -1.09e-01 |
| MESO | cg16254190 | chr1:16157199 | CGI:chr1:16154989-16155965 | promoter | 7.17e-01 | 8.32e-01 | -2.01e+00 | 4.46e-02 | 4.86e-02 | -1.16e-01 |
| ACC | cg09178261 | chr1:16156323 | CGI:chr1:16154989-16155965 | promoter | 3.81e-01 | 5.49e-01 | -2.74e+00 | 6.13e-03 | 1.94e-02 | -1.68e-01 |
Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg16254190 | chr1:16157199 | CGI:chr1:16154989-16155965 | promoter | 8.55e-01 | 9.61e-01 | -6.57e+00 | 4.87e-11 | 1.81e-09 | -1.06e-01 |
| BLCA | cg26793227 | chr1:16157163 | CGI:chr1:16154989-16155965 | promoter | 7.64e-01 | 9.05e-01 | -3.25e+00 | 1.15e-03 | 2.54e-03 | -1.42e-01 |
| BLCA | cg16254190 | chr1:16157199 | CGI:chr1:16154989-16155965 | promoter | 8.25e-01 | 9.39e-01 | -3.34e+00 | 8.50e-04 | 2.00e-03 | -1.15e-01 |
| CHOL | cg26793227 | chr1:16157163 | CGI:chr1:16154989-16155965 | promoter | 7.63e-01 | 9.55e-01 | -3.17e+00 | 1.52e-03 | 1.07e-02 | -1.91e-01 |
| CHOL | cg15146752 | chr1:16156272 | CGI:chr1:16154989-16155965 | promoter | 3.03e-01 | 4.45e-01 | -1.99e+00 | 4.65e-02 | 4.65e-02 | -1.42e-01 |
| CHOL | cg09178261 | chr1:16156323 | CGI:chr1:16154989-16155965 | promoter | 2.32e-01 | 3.50e-01 | -2.21e+00 | 2.70e-02 | 3.50e-02 | -1.18e-01 |
Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LIHC | cg26793227 | chr1:16157163 | CGI:chr1:16154989-16155965 | promoter | 7.94e-01 | 9.10e-01 | -4.70e+00 | 2.54e-06 | 2.55e-05 | -1.16e-01 |
| KIRP | cg26793227 | chr1:16157163 | CGI:chr1:16154989-16155965 | promoter | 8.21e-01 | 9.48e-01 | -3.93e+00 | 8.64e-05 | 1.12e-03 | -1.27e-01 |
Top |
Exon skipping events with PSI in TCGA for EPHA2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
Landscape of exon skipping events across multiple cancer types. |
Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for EPHA2 |
| ∗Please access CAeditome for RNA editing annotation. |
Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for EPHA2 |
TFs related to EPHA2.∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| MESO | PLAGL2 | EPHA2 | 4.18e+00 | 9.86e-01 | 2.61e+00 | 2.90e-03 | Male-biased |
EPHA2 related gene.∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for EPHA2 |
RBPs related to ES in EPHA2.∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| STAD | SAMD4A | exon_skip_22016 | 7.19e+00 | 9.85e-01 | 6.70e+00 | 3.00e-03 | Male-biased |
| CHOL | LIN28A | exon_skip_22018 | 9.15e+00 | 5.61e-03 | 9.63e+00 | 9.92e-01 | Female-biased |
| CHOL | SAMD4A | exon_skip_22016 | 6.93e+00 | 9.81e-01 | 6.42e+00 | 4.14e-03 | Male-biased |
| KIRP | LIN28A | exon_skip_22018 | 9.31e+00 | 1.41e-02 | 9.62e+00 | 9.83e-01 | Female-biased |
| ESCA | SAMD4A | exon_skip_22016 | 7.47e+00 | 9.89e-01 | 6.70e+00 | 1.25e-03 | Male-biased |
| READ | LIN28A | exon_skip_22018 | 9.59e+00 | 9.94e-01 | 9.15e+00 | 3.15e-03 | Male-biased |
| THCA | LIN28A | exon_skip_22018 | 9.58e+00 | 9.89e-01 | 9.28e+00 | 8.57e-03 | Male-biased |
| THCA | SAMD4A | exon_skip_22016 | 6.45e+00 | 1.18e-04 | 7.18e+00 | 9.88e-01 | Female-biased |
| KICH | LIN28A | exon_skip_22018 | 9.18e+00 | 6.35e-03 | 9.54e+00 | 9.91e-01 | Female-biased |
EPHA2 related ES.∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs200459 | chr1:6643747:A:C | - | -0.221958411259462 | 0.0308121279649032 | PCPG | Female-baised eQTL |
| rs9430167 | chr1:11007735:T:A | - | -0.159638508517447 | 0.00994163886378122 | KIRP | Female-baised eQTL |
| rs1293259 | chr1:25369344:G:A | - | 0.10221927829997 | 0.000128531795770075 | LGG | Female-baised eQTL |
| rs644592 | chr1:25376665:C:T | - | 0.0936441631685808 | 0.000420611926218552 | LGG | Female-baised eQTL |
| rs17350970 | chr1:13889655:C:T | - | 0.0952175953523854 | 0.00378246923892615 | LGG | Female-baised eQTL |
| rs609320 | chr1:25390874:C:G | - | 0.0794177082228652 | 0.0039557940705502 | LGG | Female-baised eQTL |
| rs61772234 | chr1:7488601:T:C | - | 0.105337943833897 | 0.0133681133422081 | LGG | Female-baised eQTL |
| rs61111144 | chr1:7492374:G:C | - | 0.101194397965365 | 0.0207053652802856 | LGG | Female-baised eQTL |
| rs201613528 | chr1:7498838:G:A | - | 0.100861679401044 | 0.0260636819053389 | LGG | Female-baised eQTL |
| rs10803469 | chr1:14163970:G:A | - | 0.085656599227575 | 0.0369773372960148 | LGG | Female-baised eQTL |
| rs10864304 | chr1:7497092:A:G | - | 0.0803845079568879 | 0.0490243383253202 | LGG | Female-baised eQTL |
| rs11580767 | chr1:7096229:C:T | - | 0.0572680290270168 | 0.00129242677253962 | LUAD | Female-baised eQTL |
| rs10927695 | chr1:15167043:A:G | - | -0.080814560163762 | 0.00148603727942031 | LUAD | Female-baised eQTL |
| rs1883760 | chr1:15151521:A:G | - | -0.0852783507940418 | 0.00167778305001477 | LUAD | Female-baised eQTL |
| rs761300 | chr1:15146391:T:C | - | -0.0817636590555883 | 0.00457282929919186 | LUAD | Female-baised eQTL |
| rs761299 | chr1:15146686:A:G | - | -0.0817636590555883 | 0.00457282929919186 | LUAD | Female-baised eQTL |
| rs9659498 | chr1:15148420:T:C | - | -0.0817636590555883 | 0.00457282929919186 | LUAD | Female-baised eQTL |
| rs2064366 | chr1:15145874:A:G | - | -0.081119146286833 | 0.00518789096019431 | LUAD | Female-baised eQTL |
| rs12755217 | chr1:6862943:G:A | - | 0.0585751136100287 | 0.00740179782132488 | LUAD | Female-baised eQTL |
| rs941456 | chr1:15145235:T:C | - | -0.0782303185450353 | 0.0110663123944668 | LUAD | Female-baised eQTL |
| rs941455 | chr1:15145292:T:C | - | -0.0782303185450353 | 0.0110663123944668 | LUAD | Female-baised eQTL |
| rs75579162 | chr1:6884036:G:T | - | 0.0571398425236569 | 0.0115900165645641 | LUAD | Female-baised eQTL |
| rs114229461 | chr1:16435908:A:G | - | 0.0786446179160491 | 0.011688153255042 | LUAD | Female-baised eQTL |
| rs74322933 | chr1:16437144:G:A | - | 0.0786278897676729 | 0.011691854213817 | LUAD | Female-baised eQTL |
| rs143321139 | chr1:16438006:T:C | - | 0.0786278897676729 | 0.011691854213817 | LUAD | Female-baised eQTL |
| rs77023128 | chr1:16439197:T:C | - | 0.0786278897676729 | 0.011691854213817 | LUAD | Female-baised eQTL |
| rs114024565 | chr1:16440864:A:G | - | 0.0786278897676729 | 0.011691854213817 | LUAD | Female-baised eQTL |
| rs3737685 | chr1:15153909:T:C | - | -0.0705460732523436 | 0.0133177990768209 | LUAD | Female-baised eQTL |
| rs12408254 | chr1:22223864:A:G | - | 0.0384188503091587 | 0.027091174035217 | LUAD | Female-baised eQTL |
| rs10917181 | chr1:22230251:A:T | - | 0.0373537721347791 | 0.0368333351947287 | LUAD | Female-baised eQTL |
| rs666103 | chr1:10451532:T:C | - | -0.0684064333575183 | 0.0402747812349306 | LUAD | Female-baised eQTL |
| rs10799635 | chr1:20442905:T:A | - | 0.0412104567034054 | 0.0426884073167772 | LUAD | Female-baised eQTL |
| rs765131 | chr1:22224878:A:G | - | 0.036934046443114 | 0.0458960225281111 | LUAD | Female-baised eQTL |
| rs1063984 | chr1:19259800:A:G | - | 0.0667382098067203 | 0.0238290983442436 | COAD | Female-baised eQTL |
| rs10917277 | chr1:19253475:A:G | - | 0.063161437394513 | 0.0319231594163506 | COAD | Female-baised eQTL |
| rs947530 | chr1:19254332:A:G | - | 0.063161437394513 | 0.0319231594163506 | COAD | Female-baised eQTL |
| rs947531 | chr1:19254363:G:C | - | 0.063161437394513 | 0.0319231594163506 | COAD | Female-baised eQTL |
| rs735026 | chr1:19254732:G:A | - | 0.063161437394513 | 0.0319231594163506 | COAD | Female-baised eQTL |
| rs1774081 | chr1:19254973:C:T | - | 0.063161437394513 | 0.0319231594163506 | COAD | Female-baised eQTL |
| rs947532 | chr1:19255440:G:T | - | 0.063161437394513 | 0.0319231594163506 | COAD | Female-baised eQTL |
| rs9426684 | chr1:19259409:G:A | - | 0.0673898405697705 | 0.0368027193708949 | COAD | Female-baised eQTL |
Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs12145857 | chr1:9423329:G:A | - | 0.087284201614242 | 0.000254178084268324 | LIHC | Male-baised eQTL |
| rs2746468 | chr1:17030776:G:C | - | 0.0742781355865738 | 0.0289353137919704 | KIRC | Male-baised eQTL |
| rs2746467 | chr1:17031120:G:A | - | 0.0742781355865738 | 0.0289353137919704 | KIRC | Male-baised eQTL |
| rs2647159 | chr1:17034125:C:G | - | 0.0727056601317987 | 0.0333223700387622 | KIRC | Male-baised eQTL |
| rs2647156 | chr1:17039578:T:C | - | 0.0727056601317987 | 0.0333223700387622 | KIRC | Male-baised eQTL |
| rs2746465 | chr1:17042128:G:A | - | 0.0727056601317987 | 0.0333223700387622 | KIRC | Male-baised eQTL |
| rs2647169 | chr1:17044728:C:T | - | 0.0727056601317987 | 0.0333223700387622 | KIRC | Male-baised eQTL |
| rs9325648 | chr1:17047506:G:A | - | 0.0725584026669636 | 0.0342482655243093 | KIRC | Male-baised eQTL |
| rs61333575 | chr1:25047225:C:T | - | 0.0906072165074058 | 0.00132237420209902 | LUAD | Male-baised eQTL |
| rs12143266 | chr1:25044607:A:T | - | 0.081974257311619 | 0.015578819292275 | LUAD | Male-baised eQTL |
| rs72657097 | chr1:25042964:C:T | - | 0.0814540980683396 | 0.018789832918551 | LUAD | Male-baised eQTL |
| rs284281 | chr1:10606460:T:G | - | -0.0819532351628743 | 0.0229356730527694 | LUAD | Male-baised eQTL |
| rs479407 | chr1:10613137:G:A | - | -0.0786497954622506 | 0.0347462941768376 | LUAD | Male-baised eQTL |
| rs284271 | chr1:10594312:A:G | - | -0.0829915117546208 | 0.0400767619381548 | LUAD | Male-baised eQTL |
| rs11249237 | chr1:25010935:C:T | - | 0.0597695985730445 | 0.0484158133582002 | LUAD | Male-baised eQTL |
| rs61761364 | chr1:18838109:G:A | - | 0.0637666065838751 | 0.0365222229672846 | COAD | Male-baised eQTL |
| rs11261089 | chr1:18835539:G:C | - | 0.0629349831491788 | 0.0407634020543112 | COAD | Male-baised eQTL |
Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg21647035 | chr1:16146984 | gene | -0.485051737461508 | 2.34425017206902e-43 | -0.7059287830187096 | 6.787113743695362e-45 | LGG |
Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg27525524 | chr1:16141818 | gene | -0.448048550066742 | 7.81993978869943e-16 | -0.8331613072476644 | 6.11826842784673e-20 | KIRP |
| cg26371327 | chr1:16146648 | gene | -0.274684635850416 | 6.71436365123776e-08 | -0.391138126902549 | 3.69052733785067e-10 | LGG |
Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of EPHA2 |
Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000142627 | EPHA2 | C0006826 | Malignant Neoplasms | 1 | CTD_human |
| ENSG00000142627 | EPHA2 | C0027651 | Neoplasms | 1 | CTD_human |
| ENSG00000142627 | EPHA2 | C0028326 | Noonan Syndrome | 1 | CTD_human |
| ENSG00000142627 | EPHA2 | C0041409 | Turner Syndrome, Male | 1 | CTD_human |
| ENSG00000142627 | EPHA2 | C0086692 | Benign Neoplasm | 1 | CTD_human |
| ENSG00000142627 | EPHA2 | C0175704 | LEOPARD Syndrome | 1 | CTD_human |
| ENSG00000142627 | EPHA2 | C0235874 | Disease Exacerbation | 1 | CTD_human |
| ENSG00000142627 | EPHA2 | C1527404 | Female Pseudo-Turner Syndrome | 1 | CTD_human |
| ENSG00000142627 | EPHA2 | C1861825 | CATARACT, POSTERIOR POLAR, 1 | 1 | CTD_human |
| ENSG00000142627 | EPHA2 | C4551484 | Leopard Syndrome 1 | 1 | CTD_human |
| ENSG00000142627 | EPHA2 | C4551602 | Noonan Syndrome 1 | 1 | CTD_human |